A Study on Paxlovid Once in the Market, to Observe Its Safety and Effectiveness in Patients Who Have a High Chance of Getting Severe COVID-19
← catalyst calendarNCT05890612 · readout in 912 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
3,000estimated
Sites
1
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-29 | actual | When the study began enrolling |
| Primary completion | 2029-02-17 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-02-17 | estimated | The whole study's end, after follow-up |
| First posted | 2023-06-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- COVID-19
Primary outcomes
what the primary-completion date above is the date OFProportion of patients with an adverse event (AE)
measured Baseline through Day 33
Proportion of patients with an adverse drug reaction (ADR)
measured Baseline through Day 33
Proportion of patients with a serious AE (SAE)
measured Baseline through Day 33
Proportion of patients with a serious ADR (SADR)
measured Baseline through Day 33
Proportion of patients with an unexpected AE (UAE)
measured Baseline through Day 33
Proportion of patients with an unexpected ADR (UADR)
measured Baseline through Day 33
Proportion of patients with a serious unexpected AE (SUAE)
measured Baseline through Day 33
Proportion of patients with a serious unexpected ADR (SUADR)
measured Baseline through Day 33
Proportion of COVID-19-related hospitalization from any cause
measured Baseline through Day 33
Proportion of COVID-19-related death from any cause
measured Baseline through Day 33
Proportion of subjective assessment of COVID-19-related symptomatic change
measured Day 5, Day 14, Day 33
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed